Search
Jean Bernard Lifetime Achievement Award
The Jean Bernard Lifetime Achievement Award was established in 2008 to honor outstanding physicians and scientists for their lifetime contribution to the advancement of hematology.
Read moreThe 3rd EHA-ISHBT Hematology Tutorial on Lymphoproliferative and Plasma Cell Disorders
The 3rd EHA-ISHBT Hematology Tutorial on Lymphoproliferative and Plasma Cell Disorders was held on February 16-18 in Lucknow, India, and chaired by Dr AK Tripathi (King George’s Medical University, Lucknow, India) and Prof G Gaidano (University of Eastern Piedmont, Novara,…
Read moreThe new EU clinical trials map is online
A new clinical trial map was launched by EMA as part of the Clinical Trials Information System (CTIS) on March 3.
Read morePediatric Hematology Online Forum
A bimonthly online event about complex cases that early-career doctors might encounter. What is the Pediatric Hematology Online Forum?The forum is an initiative of the Educational Subcommittee of the EHA SWG on Pediatric Hematology.
Read moreEHA-AAH Balkan Hematology Tutorial 2022
EHA is joined forces with the Albanian Association of Hematology (AAH) to organize the EHA-AAH Balkan Hematology Tutorial.
Read moreSession information—March 13, 2025
Topic'Primary Immunodeficiencies in Pediatric Hematooncology Practice. '
Speaker detailsCamilla Visconti (speaker)Dr Camilla Visconti is a final-year fellow in the Pediatric Immunology and BMT Unit at San Raffaele Hospital in Milan, where she manages children with inborn errors of immunity.
Highlights from the SWG
During 2023, the SWG:
Held a joint scientific meeting with the SWG on Myelodysplastic Syndromes and the SWG on Acute Myeloid Leukemia
Commenced work on guidelines for young MPN patients
Delivered a presentation for the American Society of Hematology (ASH) on the database…
Novel basis for chemoresistance in AML: DNMT3A R882 mutations promote chemoresistance and residual disease through impaired DNA damage sensing
Although most acute myeloid leukemia (AML) patients initially respond to chemotherapy, the majority subsequently relapses and succumbs to refractory disease. Residual leukemic cells that survived chemotherapy may persist over time and later cause the disease to come back.
Read more- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- 138
- 139
- 140
- 141
- 142
- 143
- 144
- 145
- 146
- 147
- 148
- 149
- 150
- 151
- »